Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Delayed Care: Research Paints Complex Picture of Treatment Delays

Thomas R. Collins  |  Issue: September 2018  |  September 11, 2018

AMSTERDAM—A variety of factors lead to delays in patients seeking medical care for rheumatoid arthritis—from the nature of symptoms to coping tendencies—requiring more awareness from physicians when managing patients, researchers said at EULAR: the Annual European Congress of Rheumatology.

Longer delays in treatment bring about more emotional distress to patients, missed chances to ease symptoms and higher healthcare costs, underscoring the need to sort out why delays happen and try to correct these problems, said Rebecca Stack, PhD, a lecturer in psychology and research at Nottingham Trent University.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

She said findings show big disparities in treatment delay exist at centers in different regions across Europe.1 For example, centers in Birmingham report 12 weeks of delay attributed to patients, whereas centers in Vienna report two weeks of delay due to patients. Centers in Stockholm report two weeks of delay attributed to appointment delays and other causes from healthcare professionals, while centers in Berlin report 10 weeks of delay for those kinds of reasons.

This, Dr. Stack said, shows there is room for improvement in getting patients treatment more quickly.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Data collected from 822 patients in the United Kingdom who were newly presenting with symptoms found that 5.7 weeks of delay were attributed to patients, seven were due to delays by the general practitioner, and 4.8 weeks were due to other delays. Fewer than 20% of the patients saw a rheumatologist within 12 weeks of symptom onset, Dr. Stack said.

Patients with a palindromic symptom onset, in which symptoms moved about or came and went, had a longer delay in treatment than those with non-palindromic symptoms. And patients with an insidious symptom emergence had a longer delay than those with acute emergence, she said.

“We know now that symptom onset is really important,” she said.

Patients try a variety of things before actually seeking professional medical help, including using ice or heat and changing their diet, she said.

“They were more likely to seek spiritual guidance than they were to actually speak to a pharmacist,” Dr. Stack said. “So we know there is potential for pharmacists to offer some interventions and to offer, perhaps, some advice to people.”

She said that better messaging with these issues in mind could help limit patient delay, “as long a they’re put into these communication messages with some sort of psychological theory behind them. … We know we need to also increase their cues to action and their self-efficacy.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:delayed careEULAREuropepatientRheumatoid Arthritis (RA)

Related Articles

    Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances

    May 8, 2012

    Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.

    Nelosa/shutterstock.com

    Men, Women & Medical Differences in Axial Spondyloarthropathy

    October 24, 2019

    Historically, ankylosing spondylitis was considered mainly a male disease. But it has become evident this predominance is not as great as previously believed. Here we discuss recent developments in the area, including potential differences between the sexes in symptom and disease burden, immunological and genetic background, diagnostic delay, treatment response and ongoing research questions. Medical…

    To Measure is to Know

    October 1, 2007

    Piet van Riel, MD, PhD, shepherd of RA improvement criteria

    “A Common Language for Spondyloarthritis”

    December 1, 2010

    ASAS fills a niche, changes dogma with consensus approach

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences